AT 1001

• Description:

  AT 1001 is a high-affinity and selective antagonist of the α3β4 nicotinic acetylcholine receptor (α3β4 nAChR) (Ki=2.64 nM) . AT 1001 reversibly blocks inward currents induced by Epibatidine (HY-101078) in HEK cells transfected with α3β4 nAChR. AT-1001 dose-dependently inhibits nicotine self-administration behavior in rats without affecting food-reinforced responding. AT 1001 can be utilized in the research of nicotine addiction and smoking cessation therapies[1].

• UNSPSC:

  12352005

• Hazard Statement:

  H315, H319, H320

• Target:

  NAChR

• Type:

  Reference compound

• Related Pathways:

  Membrane Transporter/Ion Channel; Neuronal Signaling

• Field of Research:

  Neurological Disease

• Assay Protocol:

  https://www.medchemexpress.com/at-1001.html

• Purity:

  99.94

• Smiles:

  BrC(C=CC=C1)=C1N[C@H]2C[C@@H]3N(C)[C@@H](CCC3)C2

• Molecular Formula:

  C15H21BrN2

• Molecular Weight:

  309.24

• Precautions:

  H315, H319, H320

• References & Citations:

  [1]Toll L, et al. AT-1001: a high affinity and selective α3β4 nicotinic acetylcholine receptor antagonist blocks nicotine self-administration in rats[J]. Neuropsychopharmacology, 2012, 37 (6) : 1367-1376.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  [1314801-63-2]